Molecular imaging of hepatocellular carcinoma xenografts with epidermal growth factor receptor targeted affibody probes

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Zhao, Ping ^a,b   Yang, Xiaoyang ^c   Qi, Shibo ^b   Liu, Hongguang ^b   Jiang, Han ^b   Hoppmann, Susan ^b   Cao, Qizhen ^b   Chua, Mei Sze ^c   So, Samuel K ^c   Cheng, Zhen ^b  

^a JILIN UNIVERSITY   (China)

^b STANFORD UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER 64; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR TETRAXETAN COPPER 64; FLUORESCENT DYE; TETRAXETAN; UNCLASSIFIED DRUG; (Z(EGFR)-1907)2 AFFIBODY; HYBRID PROTEIN; (Z(EGFR) 1907)2 AFFIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER PROGNOSIS; CARCINOGENESIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EARLY DIAGNOSIS; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIVER CELL CARCINOMA; MALE; MOLECULAR IMAGING; MOLECULAR PROBE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; DRUG SCREENING; GENETICS; IMMUNOLOGY; LIVER NEOPLASMS; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE; LIVER TUMOR;

ANIMALS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; EARLY DETECTION OF CANCER; HUMANS; LIVER NEOPLASMS; MICE; MOLECULAR IMAGING; NEOPLASM STAGING; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878126867     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/759057     Document Type: Article

References (39)

1. Llovet J. M., Burroughs A., Bruix J., Hepatocellular carcinoma. The Lancet 2003 362 9399 1907 1917 2-s2.0-0141491273 10.1016/S0140-6736(03)14964-1 (Pubitemid 37518510)
2. Okuda K., Hepatocellular carcinoma. Journal of Hepatology 2000 32 1 225 237 2-s2.0-0034090264 (Pubitemid 30123637)
3. Parkin D. M., Pisani P., Ferlay J., Global cancer statistics. Ca: A Cancer Journal for Clinicians 1999 49 1 33 64 2-s2.0-0033008968 (Pubitemid 29094960)
4. Bruix J., Sherman M., Management of hepatocellular carcinoma. Hepatology 2005 42 5 1208 1236 2-s2.0-28844480321 10.1002/hep.20933 (Pubitemid 43112690)
5. Capurro M., Wanless I. R., Sherman M., Deboer G., Shi W., Miyoshi E., Filmus J., Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003 125 1 89 97 2-s2.0-0038786861 10.1016/S0016-5085(03)00689-9 (Pubitemid 36799110)
6. Massarweh N. N., Park J. O., Farjah F., Yeung R. S. W., Symons R. G., Vaughan T. L., Baldwin L. M., Flum D. R., Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma. Journal of the American College of Surgeons 2010 210 4 441 448 2-s2.0-77949889477 10.1016/j. jamcollsurg.2009.12.026
7. Khan M. A., Combs C. S., Brunt E. M., Lowe V. J., Wolverson M. K., Solomon H., Collins B. T., Di Bisceglie A. M., Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. Journal of Hepatology 2000 32 5 792 797 2-s2.0-0034065863 10.1016/S0168-8278(00)80248-2 (Pubitemid 30262739)
8. Park J. W., Ji H. K., Seok K. K., Keon W. K., Kyung W. P., Choi J. I., Woo J. L., Kim C. M., Byung H. N., A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. Journal of Nuclear Medicine 2008 49 12 1912 1921 2-s2.0-57149101558 10.2967/jnumed.108.055087
9. Yun M., Bang S. H., Jae W. K., Jun Y. P., Kyoung S. K., Jong D. L., The importance of acetyl coenzyme A synthetase for 11C-acetate uptake and cell survival in hepatocellular carcinoma. Journal of Nuclear Medicine 2009 50 8 1222 1228 2-s2.0-68249161944 10.2967/jnumed.109.062703
10. Yoshimoto M., Waki A., Yonekura Y., Sadato N., Murata T., Omata N., Takahashi N., Welch M. J., Fujibayashi Y., Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nuclear Medicine and Biology 2001 28 2 117 122 2-s2.0-0035064665 10.1016/S0969-8051(00)00195-5 (Pubitemid 32276075)
11. Daveau M., Scotte M., François A., Coulouarn C., Ros G., Tallet Y., Hiron M., Hellot M. F., Salier J. P., Hepatocyte growth factor, transforming growth factor α and their receptors as combined markers of prognosis in hepatocellular carcinoma. Molecular Carcinogenesis 2003 36 3 130 141 2-s2.0-0037335527 10.1002/mc.10103 (Pubitemid 36314790)
12. Jiang H., Wang H., Tan Z., Hu S., Wang H., Shi B., Yang L., Li P., Gu J., Wang H., Li Z., Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III. Journal of Biological Chemistry 2011 286 7 5913 5920 2-s2.0-79953129274 10.1074/jbc.M110.192252
13. de Bruin K., Ruthardt N., von Gersdorff K., Bausinger R., Wagner E., Ogris M., Bräuchle C., Cellular dynamics of EGF receptor-targeted synthetic viruses. Molecular Therapy 2007 15 7 1297 1305 2-s2.0-34250768172 10.1038/sj.mt.6300176 (Pubitemid 46965326)
14. Herbst R. S., Review of epidermal growth factor receptor biology. International Journal of Radiation Oncology Biology Physics 2004 59 2 21 26 2-s2.0-2342492317 10.1016/j.ijrobp.2003.11.041 (Pubitemid 38610223)
15. Lupberger J., Zeisel M. B., Xiao F., Thumann C., Fofana I., Zona L., Davis C., Mee C. J., Turek M., Gorke S., Royer C., Fischer B., Zahid M. N., Lavillette D., Fresquet J., Cosset F. L., Rothenberg S. M., Pietschmann T., Patel A. H., Pessaux P., Dofföl M., Raffelsberger W., Poch O., McKeating J. A., Brino L., Baumert T. F., EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nature Medicine 2011 17 5 589 595 2-s2.0-79955692689 10.1038/nm.2341
16. Schneider M. R., Wolf E., The epidermal growth factor receptor ligands at a glance. Journal of Cellular Physiology 2009 218 3 460 466 2-s2.0-58149376976 10.1002/jcp.21635
17. Mendelsohn J., Baselga J., Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. Journal of Clinical Oncology 2003 21 14 2787 2799 2-s2.0-0041629450 10.1200/JCO.2003.01.504 (Pubitemid 46606324)
18. Schlessinger J., Cell signaling by receptor tyrosine kinases. Cell 2000 103 2 211 225 2-s2.0-0034644539
19. Real F. X., Rettig W. J., Chesa P. G., Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Research 1986 46 9 4726 4731 2-s2.0-0022452615 (Pubitemid 16000351)
20. Buckley A. F., Burgart L. J., Sahai V., Kakar S., Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. American Journal of Clinical Pathology 2008 129 2 245 251 2-s2.0-40449113855 10.1309/WF10QAAED3PP93BH (Pubitemid 352029315)
21. DeCicco L. A., Kong J., Ringer D. P., Carcinogen-induced alteration in liver epidermal growth factor receptor distribution during the promotion stage of hepatocarcinogenesis in rat. Cancer Letters 1997 111 1-2 149 156 2-s2.0-0031023904 10.1016/S0304-3835(96)04524-7 (Pubitemid 27068230)
22. Kira S., Nakanishi T., Suemori S., Kitamoto M., Watanabe Y., Kajiyama G., Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. Liver 1997 17 4 177 182 2-s2.0-0030825110 (Pubitemid 27394085)
23. Schiffer E., Housset C., Cacheux W., Wendum D., Desbois-Mouthon C., Rey C., Clergue F., Poupon R., Barbu V., Rosmorduc O., Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005 41 2 307 314 2-s2.0-19944432263 10.1002/hep.20538 (Pubitemid 40165374)
24. Friedman M., Nordberg E., Höidén-Guthenberg I., Brismar H., Adams G. P., Nilsson F. Y., Carlsson J., Ståhl S., Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Engineering, Design and Selection 2007 20 4 189 199 2-s2.0-34347380371 10.1093/protein/gzm011 (Pubitemid 351321300)
25. Gao J., Chen K., Miao Z., Ren G., Chen X., Gambhir S. S., Cheng Z., Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials 2011 32 8 2141 2148 2-s2.0-78651464824 10.1016/j.biomaterials.2010. 11.053
26. Hoppmann S., Miao Z., Liu S., Liu H., Ren G., Bao A., Cheng Z., Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting. Bioconjugate Chemistry 2011 22 3 413 421 2-s2.0-79952809888 10.1021/bc100432h
27. Miao Z., Ren G., Liu H., Qi S., Wu S., Cheng Z., PET of EGFR expression with an 18F-labeled affibody molecule. Journal of Nuclear Medicine 2012 53 7 1110 1118 10.2967/jnumed.111.100842
28. Qi S., Miao Z., Liu H., Xu Y., Feng Y., Cheng Z., Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors. Bioconjugate Chemistry 2012 23 6 1149 1156 10.1021/bc200596a
29. Yang M., Cheng K., Qi S., Affibody modified and radiolabeled gold-iron oxide hetero-nanostructures for tumor PET, optical and MR imaging. Biomaterials 2013 34 11 2796 2806 10.1016/j.biomaterials.2013.01.014
30. Nord K., Gunneriusson E., Ringdahl J., Stahl S., Uhlén M., Nygren P. A., Binding proteins selected from combinatorial libraries of an α -helical bacterial receptor domain. Nature Biotechnology 1997 15 8 772 777 2-s2.0-0030835822 (Pubitemid 27329481)
31. Friedman M., Orlova A., Johansson E., Eriksson T. L. J., Höidén-Guthenberg I., Tolmachev V., Nilsson F. Y., Ståhl S., Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. Journal of Molecular Biology 2008 376 5 1388 1402 2-s2.0-39149087035 10.1016/j.jmb.2007.12.060
32. Miao Z., Levi J., Cheng Z., Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids 2011 41 5 1037 1047 10.1007/s00726-010- 0503-9
33. Cheng Z., De Jesus O. P., Namavari M., De A., Levi J., Webster J. M., Zhang R., Lee B., Syud F. A., Gambhir S. S., Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. Journal of Nuclear Medicine 2008 49 5 804 813 2-s2.0-44149108464 10.2967/jnumed.107.047381 (Pubitemid 351717547)
34. Sogawa C., Tsuji A. B., Yoshida C., Novel human monoclonal antibody against epidermal growth factor receptor as an imaging probe for hepatocellular carcinoma. Nuclear Medicine Communications 2012 33 7 719 725 10.1097/MNM.0b013e3283531d68
35. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of Controlled Release 2000 65 1-2 271 284 2-s2.0-0034000453 10.1016/S0168-3659(99)00248-5 (Pubitemid 30122932)
36. Tolmachev V., Orlova A., Pehrson R., Galli J., Baastrup B., Andersson K., Sandström M., Rosik D., Carlsson J., Lundqvist H., Wennborg A., Nilsson F. Y., Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific affibody molecule. Cancer Research 2007 67 6 2773 2782 2-s2.0-33947672248 10.1158/0008-5472.CAN-06-1630 (Pubitemid 46548966)
37. Orlova A., Feldwisch J., Abrahmsén L., Tolmachev V., Update: affibody molecules for molecular imaging and therapy for cancer. Cancer Biotherapy and Radiopharmaceuticals 2007 22 5 573 584 2-s2.0-35848936085 10.1089/cbr.2006.004-U (Pubitemid 350058993)
38. Miao Z., Ren G., Liu H., Jiang L., Cheng Z., Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein. Bioconjugate Chemistry 2010 21 5 947 954 2-s2.0-77952565937 10.1021/bc900515p
39. Nagengast W. B., De Vries E. G., Hospers G. A., Mulder N. H., De Jong J. R., Hollema H., Brouwers A. H., Van Dongen G. A., Perk L. R., Lub-de Hooge M. N., In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. Journal of Nuclear Medicine 2007 48 8 1313 1319 2-s2.0-34547736456 10.2967/jnumed.107.041301 (Pubitemid 47242797)